Remove 2023 Remove Chemotherapy Remove Generic Medicine
article thumbnail

CHMP meeting highlights – March 2023

European Pharmaceutical Review

The committee recommended granting a paediatric-use marketing authorisation (PUMA) for Pedmarqsi (sodium thiosulfate) for preventing ototoxicity induced by cisplatin chemotherapy. Ototoxicity is the development of hearing or balance problems due to a medicine. Cisplatin is a chemotherapy used to treat several types of cancer.

article thumbnail

CHMP meeting highlights: January 2024

European Pharmaceutical Review

Ryzneuta (efbemalenograstim alfa) received a positive opinion from the CHMP as a medicine to reduce the duration of neutropenia and the incidence of febrile neutropenia due to chemotherapy. Additionally, a positive opinion for Niapelf (paliperidone), a generic medicine for schizophrenia was adopted in the meeting.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Why cancer medicines are and continue to be vulnerable to drug shortages

Quality Matters

Some hospitals have reported rationing doses in response to these shortages, and the American Society of Clinical Oncologists (ASCO) has issued new clinical guidance for treating patients with gastrointestinal (GI) cancers, which are commonly treated with carboplatin and cisplatin, two chemotherapy agents currently in shortage nationwide.

article thumbnail

Identifying upstream supply chain vulnerabilities can help mitigate or prevent drug shortages

Quality Matters

Identifying upstream supply chain vulnerabilities can help mitigate or prevent drug shortages After Laura Bray’s daughter was diagnosed with cancer and began chemotherapy treatment, she faced three separate shortages of the life-saving drugs she needed, all within nine months. kristine.gates… Mon, 05/22/2023 - 10:48 Supply Chain